Despite widespread clinical use of antimalarial drugs such as hydroxychloroquine and
chloroquine in the treatment of rheumatoid arthritis (RA), systemic lupus erythematosus …

The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is
now challenging the entire lupus community, from geneticists to clinical investigators …

The antimalarial hydroxychloroquine (HCQ) has demonstrated several crucial properties for
the treatment of systemic lupus erythematosus (SLE). Herein, we reviewed the main HCQ …

Childhood-onset systemic lupus erythematosus (cSLE) is a prototype of a multisystemic,
inflammatory, heterogeneous autoimmune condition. This disease is characterized by …

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease
affecting both adults and children. Belimumab is the only biologic approved for SLE, and the …

Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid
mechanism of action, low cost, and accessibility have made them one of the mainstays of …

Objective To determine the independent impact of different definitions of remission and low
disease activity (LDA) on damage accrual. Methods Patients with≥ 2 annual assessments …

Systemic lupus erythematosus (SLE) is the paradigm of systemic autoimmune diseases
characterised by a wide spectrum of clinical manifestations with an unpredictable relapsing …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which multiple
organs are damaged by the immune system. Although standard treatment options such as …

Aim The aim of this study was to identify factors predictive of serious infections over time in
patients with systemic lupus erythematosus (SLE). Methods A multi-ethnic, multi-national …